HIV infection and pathogenesis: What about chemokines?

Journal of Clinical Immunology

Volumn 19, Issue 5, 1999, Pages 293-299

  Gallo, Robert C ^a   Garzino Demo, Alfredo ^a   DeVico, Anthony L ^a  

^a INSTITUTE OF HUMAN VIROLOGY   (United States)

Author keywords

Chemokines; HIV; HIV infection; HIV pathogenesis

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOSAMINOGLYCAN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION;

ANIMALS; CHEMOKINES; HIV; HIV INFECTIONS; HUMANS;

EID: 0032857669     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020539524373     Document Type: Review

References (68)

1. 1. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G-protein coupled receptor. Science 272:872-877, 1996
2. 2. Alkhatib G, Combardiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA: CC-CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-1958, 1996
3. 3. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath P, Lijun W, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodrosky J: The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148, 1996
4. 4. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR: Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666, 1996
5. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673, 1996
6. 6. Doranz BJ, Rucker J, Yi YJ, Smith RJ, Samson M, Peiper SC, Parmentier M, Cullman RG, Doms RW: A dual tropic primary isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3 and CKR-2B as fusion cofactors. Cell 85:1149-1158, 1996
7. 7. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien SJ: Genetic restriction of HIV-1 infeclion and progression to ATDS by a deletion allele of the CKR5 structural gene Science 273:1856-1862, 1996
8. 8. Samson M, Liberi F, Doranz, BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725, 1996
9. 9. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, Koup RA: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2:1240-1243, 1996
10. 10. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377, 1996
11. 11. Zimmerman PA, Bucklerwhite A, Alkhatib G, Spalding T, Kubofcik JA, Combardiere C, Weissman DA, Cohen O, Rubbert AA, Lam G, Vaccarezza MA, Kennedy PE, Kumaraswami VA, Giorgi JV, Detels R, Hunter J, Chopek M, Berger EA, Fauci AS, Nutman TB, Murphy PM: Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor-5-studies in populations with contrasting clinical phenotypes, defined racial backgrounds, and quantified risk. Mol Med 3:23-36, 1997
12. 12. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, Sheppard HW: The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 3:338-340, 1997
13. 13. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitmun SF, Murphy PM: CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 352:866-870, 1998
14. 14. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT, Craig FE, O'Connell P, Tryon V, Clark RA, Dolan MJ, Ahuga SK: Genealogy of the CCRS locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 4:786-793, 1998
15. 15. Schols D, Struyf S, Van Damme J, Este JA, Henson G, De Clercq, F: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 186:1383-1388, 1997
16. 16. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, Yoshida N, Waki M, Matsumoto A, Yoshie O, Kishimoto T, Yamamoto N, Nagasawa T: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 186:1389-1393, 1997
17. 17. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, Doms RW, O'Brien WA: A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 186:1395-1400, 1997
18. 18. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, DeClercq E, Moore JP: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4:72-77, 1998
19. + cells. Science 270:1811-1815, 1995
20. 20. Dolei A, Biolchini A, Serra C, Curreli S, Gomes E, Dianzani F: Increased replication of T-cell-tropic HIV strains and CXC-chemokine receptor-4 induction in T cells treated with macrophage inflammatory protein (MIP)-1α, MIP-1β and RANTES β-chemokines. AIDS 12:183-190, 1998
21. 21. Kinter A, Catanzaro A, Monaco J, Ruiz M, Justement J, Moir S, Arthos J, Oliva A, Ehler L, Mizell S, Jackson R, Ostrowski M, Hoxic J, Offord R, Fauci AS: CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: Role of signal transduction. Proc Natl Acad Sci USA 95:11880-11885, 1998
22. 22. Gordon CJ, Muesing MA, Proudfoot AE, Power CA, Moore JP, Trkola A: Enhancement of human immunodeficiency virus type I infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion. J Virol 73:684-694, 1999
23. 23. Zanussi S, D'Andrea M, Simonelli C, Tirelli U, De Paoli P: Serum levels of RANTES and MIP-1α in HIV-positive long-term survivors and progressor patients. AIDS 10:1431-1432, 1996
24. 24. Weiss L, Si-Mohamed A, Giral P, Castiel P, Ledur A, Blondin C, Kazatchkine MD, Haeffner-Cavaillon N: Plasma levels of monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1α and RANTES correlate with virus load in human immunodeficiency virus infection. J Infect Dis 176:1621-1624, 1997
25. 25. Hittinger G, Poggi C, Delbeke E, Profizi N, Lafeuillade A: Correlation between plasma levels of cytokines and HIV-1 RNA copy number in HIV-infected patients. Infection 26:100-103, 1998
26. 26. McKenzie SW, Dallalio G, North M, Frame P, Means RT: Serum chemokine levels in patients with non-progressing HIV infection. AIDS 10:F29-F33, 1996
27. 27. Krowka JF, Gesner ML, Ascher MS, Sheppard HW: Lack of associations of chemotactic cytokines with viral burden, disease progression, or lymphocyte subsets in HIV-infected individuals. Clin Immunol Immunopathol 85:21-27, 1997
28. 28. Kakkanaiah VN, Ojo-Amaize EA, Peter JB: Concentrations of circulating beta-chemokines do not correlate with viral load in human immunodeficiency virus-infected individuals. Clin Diagn Lab Immunol 5:499-502, 1998
29. 29. Polo S, Veglia F, Malnati MS, Gobbi C, Farci P, Raiteri R, Sinicco A, Lusso P: Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection, AIDS 13:447 454, 1999
30. 30. Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM: Cytokine RANTRS released by thrombin-stimulaled platelets is a potent attractant for human eosinophils. J Exp Med 176:587-592, 1992
31. 31. Power CA, Clemetson JM, Clemetson KJ, Wells TN: Chemokine and chemokine receptor mRNA expression in human platelets. Cytokine 7:479-482, 1995
32. 32. Klinger MH, Wilhelm D, Bubel S, Sticherling M, Schroder JM, Kuhnel W: Immunocytochemical localization of the chemokines RANTES and MIP-1α within human platelets and their release during storage. Int Arch Allergy Immunol 107:541 546, 1995
33. 33. Bubel S, Wilhelm D, Entelmann H, Kirchner U, Kluter H: Chemokines in stored platelet concentrates. Transfusion 36:445-449, 1996
34. 34. Holme PA, Muller F, Solum NO, Brosstad F, Froland SS, Aukrust P: Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type I infection. FASEB J 12:79-89, 1998
35. 35. Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell E, Tao L, Hall G, Dennis M, Cook N, Brookes R, Klavinskis L, Jones I, Doyle C, Ward R: Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 2:767-775, 1996
36. 36. Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell L, Tao L, Hall G, Dennis M, Cook N, Jones I, Doyle C: Protective mucosal immunity elicited by targeted lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Dev Biol Stand 92:225-235, 1998
37. 37. Wang Y, Tao L, Mitchell E, Bogers WM, Doyle C, Bravery CA, Bergmeier LA, Kelly CG, Heeney JL, Lehner T: Generation of CDS suppressor factor and beta chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus infection in macaques. Proc Natl Acad Sci USA 95:5223-5228, 1998
38. 38. Heeney JL, Teeuwsen VJ, van Gils M, Bogers WM, De Giuli Morghen C, Radaelli A, Barnett S, Morein B, Akerblom L, Wang Y, Lehner T, Davis D: β-Chemokines and neutralizing antibody liters correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc Natl Acad Sci USA 95:10803-10808, 1998
39. 27 challenge. J Gen Virol 80:1569-1574, 1998
40. 40. Moss RB, Trauger RJ, Giermakowska WK, Turner JL, Wallace MR, Jensen FC, Richieri SP, Ferre F, Daigle AE, Duffy C, Theofan G, Carlo DJ: Effect of immunization wild an inactivated gp120-depleted HIV-1 immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 14:343-350, 1997
41. 41. Moss RB, Wallace MR, Lanza P, Giermakowska W, Jensen FC, Theofan G, Chamberlin C, Richieri SP, Carlo DJ: In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus typo I (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune). Clin Diag Lab Immunol 5:308-312, 1998
42. 42. Zagury D, Lachgar A, Charns V, Fall LS, Bernard J, Zagury JF, Bizzini B, Gringieri A, Santagostino E, Rappaport J, Feldman M, O'Brien SJ, Burny A, Gallo RC: C-C chemokines, pivotal in protection against HIV type I infection. Proc Natl Acad Sci USA 95:3857-3861, 1998
43. 43. Paxton WA, Liu R, Kang S, Wu L, Gingeras TR, Landau NR, Mackay CR, Koup RA: Reduced HIV 1 infectabilily of CD4+ lymphocytes from exposed-uninfected individuals: Association with low expression of CCR5 and high production of β-chemo kines. Virology 244:66-73, 1998
44. 44. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, VanDevanter NL, Padian M, Braun JF, Kotler DP, Wolinsky SM, Koup RA: Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 2:412-417, 1996
45. 45. Ullum H, Cozzi A, Victor J, Aladdin A, Phillips AN, Gerstoft J, Skinhej P, Pedersen BK: Production of beta-chemokines in human immunodeficiency virus (HIV) infection: Evidence that high levels of macrophage inflammatory protein-1 beta are associated with a decreased risk of HIV disease progression. J Infect Dis 133:331-336, 1998
46. 46. Tartakovsky B: Turner D, Vardinonn, Burke M, Yust I: Increased intracellular accumulation of macrophage inflammatory protein 1 beta and its decreased secretion correlate with advanced HIV disease. J Acquir Immune Defic Syndr Hum Retroviruses 20:420 422, 1999
47. 47. Wagner L, Yang OO, Garcia-Zepeda EA, Ge Y, Kalams SA, Walker BD, Pasternack MS, Luster AD: β-Chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 391:908-911, 1998
48. 48. Price DA, Sewell AK, Dong T, Tan R, Goulder PJ, Rowland-Jones SL, Phillips RC: Antigen-specific release of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes. Curr Biol 8:355-358, 1998
49. 40. Wasik TJ, Bratosiewicz, J, Wierzbicki A, Whiteman VE, Rutstein RR, Starr SE, Douglas SD, Kaufman D, Sison AV, Polansky M, Lischner HW, Kozbor D: Protective role of β-chemokines associated with HIV-specific Th responses against perinatal HIV transmission. J Immunol 162:4355-4364, 1999
50. 50. Furci L, Scarlatti G, Burastero S, Tambussi G, Colognesi C, Quillent C, Longhi R, Loverro P, Borgonovo B, Galfi D, Carrow E, Malnati M, Lusso P, Siccardi AG, Lazzarin A, Beretta A: Antigendriven C-C chemokine-medialed HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med 186:455-460, 1997
51. 51. Garzino-Demo A, Moss RB, Margolick JB, Cleghorn F, Sill A, Blattner WA, Cocchi F, Carlo DJ, Devico AL, Gallo RC: Spontaneous and antigen-induced production of HIV-inhibitory β-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA, in press
52. 32. Butz EA, Bevan MJ: Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity 8:167-175, 1998
53. 53. Pantaleo G, Soudeyns H, Demarest JF, Vaccarezza M, Graziosi C, Paolucci S, Daucher M, Cohen M, Denis F, Biddison WE, Sekaly RP, Fauci AS: Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci USA 94:9848-9853, 1997
54. 54. Pal R, Garzino-Demo A, Markham PD, Burns J, Brown M, Gallo RC, DeVico AL: Inhibition of HIV-1 infection by the beta-chemokine MDC. Science 278:695-698, 1997
55. 55. Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E, Norcross MA: Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 186:1865-1872, 1997
56. 56. Struyf S, De Meester I, Scharpe S, Lenaerts JP, Menten P, Wang JM, Proost P, Van Damme J: Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur J Immunol 28:1262-1271, 1998
57. 57. Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G, De Clercq E, Scharpe S, Van Damme J: Amino-terminal truncation of chemokines by CD26/dipeptidylpeptidase TV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 273: 7222-7227, 1998
58. 58. Shioda T, Kato H, Ohnishi Y, Tashiro K, Ikegawa M, Nakayama EE, Hu H, Kato A, Sakai Y, Liu H, Honjo T, Nomoto A, Iwamoto A, Morimoto C, Nagai Y: Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1 alpha (SDF-1 alpha) and SDF-1 beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci USA 95:6331-6336, 1998
59. 59. Van Coillie E, Proost P, Van Aelst I, Struyf S, Polffiet M, De Meester I, Harvey DJ, Van Damme J, Opdenakker G: Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase 1V. Biochemistry 37:12672-12680, 1998
60. 60. Schols D, Proost P, Struyf S, Wuyts A, De Meester I, Scharpe S, Van Damme J, De Clercq E: C.D26-processed RANTES (3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res 39:175-187, 1998
61. 61. Proost P, Struyf S, Schols D, Opdenakker G, Sozzani S, Allavena P, Mantovani A, Augustyns K, Bal G, Haemers A, Lambeir AM, Scharpe S, Van Damme J, De Meester I: Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chernotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 274:3988-3993, 1999
62. 62. Nibbs RJ, Yang J, Landau NR, Mao JM, Graham GJ: LD78beta, A non-allelic variant of human MIP-1 alpha (LD78ALPHA), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem 274:17478-17483, 1999
63. 63. Oravecz T, Pall M, Wang J, Roderiquez G, Ditto M, Norcross MA: Regulation of anti-HIV-1 activity of RANTES by heparan sulfate proteoglycans. J Immunol 159:4587-9452, 1997
64. 64. Burns JM, Gallo RC, DeVico AL, Lewis GK: A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling. J Exp Med 188:1917-1927, 1998
65. 65. Amzazi S, Ylisasligui L, Bakri Y, Rabehi L, Gattegno L, Parmentier M, Gluckman JC, Benjouad A: The inhibitory effect of RANTES on the infection of primary macrophages by R5 human immunodeficiency virus type-1 depends on the macrophage activation state. Virology 252:96-105, 1998
66. 66. Farzan M, Mirzabekov T, Kolehinsky P, Wyatt R, Cayabyab M, Gerard NP, Gerard C, Sodroski J, Choe H: Tyrosine sulfation of the amino terminus of CCR-5 facilitates HIV-1 entry. Cell 96:667-676, 1999
67. 67. Fehniger TA, Herbein G, Yu H, Para MI, Bernstein ZP, O'Brien WA, Caligiuri MA: Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol 161:6433-6438, 1998
68. 68. Oliva A, Kinter AL, Vaccarezza M, Rubbert A, Catanzaro A, Moir S, Monaco J, Ehler L, Mizell S, Jackson R, Li Y, Romano JW, Fauci AS: Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokincs and suppress HIV-1 entry and replication in vitro. J Clin Invest 102:223-231, 1998